Sponsor
Mayo Clinic
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05557877
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) patients with benign breast disease planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Intervention
Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration, Ultrasound-Guided Biopsy
Condition
Benign Breast Neoplasm, Breast Carcinoma, Breast Fibrocystic Change
Investigators
Kathryn J. Ruddy, M.D., Clinical Trials Referral Office, Sarah McLaughlin, M.D., Barbara A. Pockaj, M.D.